Interestingly, a recent study has also highlighted the use of GLP‐1 agonists in ABCD patients to reduce lifetime PCa risk relating to their influence on Forkhead Box C2 (FOXC2) gene expression and insulin resistance [91]. The gene discussed is FOXC2; the disease is posterior cortical atrophy.